ProKidney Corp. (NASDAQ:PROK) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story centers on rilparencel, its experimental cell therapy for patients with advanced chronic kidney disease and type 2 diabetes. On May 15, ProKidney said it remained on track to finish enrolling patients for an important part of its PROACT 1 late-stage trial in mid-2026, with key kidney-function results expected in the second quarter of 2027.
The trial is important because the FDA has already agreed that ProKidney can use a kidney-function measure called eGFR slope as the main basis for seeking accelerated approval. In simple terms, eGFR slope tracks how quickly a patient’s kidney function is worsening over time. ProKidney also pointed to earlier Phase 2 data from the REGEN-007 study, where one patient group showed a 4.6 mL/min/1.73m² improvement in annual kidney-function decline after treatment compared with the period before injection. The company ended the first quarter with $224.9 million in cash, cash equivalents, and marketable securities, which it expects to fund operations into mid-2027.
ProKidney Corp. is a late clinical-stage biotechnology company developing rilparencel, a cell therapy made from a patient’s own kidney cells, for advanced chronic kidney disease in patients with type 2 diabetes.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.